Naftopidil treatment causes growth arrest of human lung fibroblasts and reduces fibrotic lesions in mice with idiopathic pulmonary…
Articles by Santiago Gisler
Loss of productivity in the workplace is common among patients with fibrotic interstitial lung disease (ILD), and is associated…
Indalo Therapeutics has launched a Phase 1 clinical trial testing the company’s lead antifibrotic candidate IDL-2965 for patients with…
The pulmonary fibrosis (PF) community is invited to attend the Pulmonary Fibrosis Foundation‘s PFF Summit, which is…
Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary…
Blood levels of immune cells called monocytes may help predict disease severity and determine the risk of poor outcomes in…
Envisia Genomic Classifier — a non-invasive diagnostic test developed by Veracyte and used as a complement to high-resolution computed…
Quantification of so-called honeycombing areas (patches of cystic spaces) in the lungs seen through high-resolution computed tomography (HRCT) may…
The Pulmonary Fibrosis Foundation (PFF) has opened a new registration cycle for medical centers that wish to join the…
Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF)…